Search

Your search keyword '"He, Ming-ming"' showing total 200 results
Start Over Author "He, Ming-ming"
Sorry, I don't understand your search. ×
200 results on '"He, Ming-ming"'

11. Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer

Author

Zhao, Qi, Wang, Feng, Chen, Yan-Xing, Chen, Shifu, Yao, Yi-Chen, Zeng, Zhao-Lei, Jiang, Teng-Jia, Wang, Ying-Nan, Wu, Chen-Yi, Jing, Ying, Huang, You-Sheng, Zhang, Jing, Wang, Zi-Xian, He, Ming-Ming, Pu, Heng-Ying, Mai, Zong-Jiong, Wu, Qi-Nian, Long, Renwen, Zhang, Xiaoni, Huang, Tanxiao, Xu, Mingyan, Qiu, Miao-Zheng, Luo, Hui-Yan, Li, Yu-Hong, Zhang, Dong-Shen, Jia, Wei-Hua, Chen, Gong, Ding, Pei-Rong, Li, Li-Ren, Lu, Zheng-Hai, Pan, Zhi-Zhong, and Xu, Rui-Hua

Published
2022
Full Text
View/download PDF

12. How Traditional Fishing Villages Move towards Sustainable Management: A Case Study of Industrial Transformation and Multi-Party Governance Models.

Author

He, Ming-Ming, Wang, Jing, Lee, Su-Hsin, and Tsai, Shu-Chen

Abstract

The purpose of this study is to explore the key roles and functions of institutions or organizations in the process of the spatial activation and industrial transformation of leisure fishing villages and to summarize this operating model. This study takes Xunpu Village, Quanzhou City, Fujian Province as the research object, which is well-known for its recreational fisheries. It mainly uses case study methods and uses on-site surveys and interviews to understand the formation time, spatial distribution, and business type information of the Zanhuawei shops in Xunpu Village. Zanhuawei, which refers to the traditional hairstyle of Xunpu women, was later applied for national intangible cultural heritage status in China. After the outbreak, the spread of Zanhuawei on the Internet inspired a large number of tourists to visit Xunpu Village to experience Zanhuawei. The study found that (1) Zanhuawei industry replaced traditional fishery and became the leading industry type in Xunpu Village. (2) The operating model led by the government and integrating public and private funds has had a stimulating effect on the revitalization of local commercial and residential space, and a large number of idle spaces have been reactivated. (3) The cooperation model between a large number of investors and local fisherwomen has completely changed the economic model of the village. Zanhuawei industry mobilized all official and media resources to promote spatial activation at various scales, including regions, settlements and commercial spaces. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Post‐diagnostic multivitamin supplement use and colorectal cancer survival: A prospective cohort study

Author

He, Ming‐ming, primary, Wang, Kai, additional, Lo, Chun‐Han, additional, Zhang, Yiwen, additional, Polychronidis, Georgios, additional, Knudsen, Markus D., additional, Zhong, Rong, additional, Ma, Yuan, additional, Wu, Kana, additional, Chan, Andrew T., additional, Giovannucci, Edward L., additional, Ogino, Shuji, additional, Ng, Kimmie, additional, Meyerhardt, Jeffrey A., additional, and Song, Mingyang, additional

Published
2024
Full Text
View/download PDF

22. In Utero and Childhood/Adolescence Exposure to Tobacco Smoke, Genetic Risk, and Lung Cancer Incidence and Mortality in Adulthood

Author

He, Heng, primary, He, Ming-Ming, additional, Wang, Haoxue, additional, Qiu, Weihong, additional, Liu, Lei, additional, Long, Lu, additional, Shen, Qian, additional, Zhang, Shanshan, additional, Qin, Shifan, additional, Lu, Zequn, additional, Cai, Yimin, additional, Zhang, Ming, additional, Niu, Siyuan, additional, Li, Jiaoyuan, additional, Shen, Na, additional, Zhu, Ying, additional, Tian, Jianbo, additional, Chang, Jiang, additional, Miao, Xiaoping, additional, and Zhong, Rong, additional

Published
2023
Full Text
View/download PDF

23. Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials

Author

Wei, Xiao-Li, primary, Zhang, Yang, additional, Zhao, Hong-Yun, additional, Fang, Wen-Feng, additional, Luo, Hui-Yan, additional, Qiu, Miao-Zhen, additional, He, Ming-Ming, additional, Zou, Ben-Yan, additional, Xie, Jie, additional, Jin, Chun-Lei, additional, Zhou, Xian-Feng, additional, Wang, Feng, additional, Wang, Feng-Hua, additional, Li, Yu-Hong, additional, Wang, Zhi-Qiang, additional, and Xu, Rui-Hua, additional

Published
2022
Full Text
View/download PDF

26. A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)

Author

Wang, Feng, primary, He, Ming-Ming, additional, Xiao, Jian, additional, Zhang, Yan-Qiao, additional, Yuan, Xiang-Lin, additional, Fang, Wei-Jia, additional, Zhang, Yan, additional, Wang, Wei, additional, Hu, Xiao-Hua, additional, Ma, Zhi-Gang, additional, Yao, Yi-Chen, additional, Zhuang, Zhi-Xiang, additional, Zhou, Fu-Xiang, additional, Ying, Jie-Er, additional, Yuan, Ying, additional, Zou, Qing-Feng, additional, Guo, Zeng-Qing, additional, Wu, Xiang-Yuan, additional, Jin, Ying, additional, Mai, Zong-Jiong, additional, Wang, Zhi-Qiang, additional, Qiu, Hong, additional, Guo, Ying, additional, Shi, Si-Mei, additional, Chen, Shuang-Zhen, additional, Luo, Hui-Yan, additional, Zhang, Dong-Sheng, additional, Wang, Feng-Hua, additional, Li, Yu-Hong, additional, and Xu, Rui-Hua, additional

Published
2022
Full Text
View/download PDF

27. Mutational profiles of sporadic synchronous colorectal cancer.

Author

Yang, Lu-Ping, primary, Jiang, Teng-Jia, additional, He, Ming-ming, additional, Zhao, Qi, additional, Ling, Yihong, additional, Wang, Zi-xian, additional, Wu, Hao-Xiang, additional, Jin, Ying, additional, Zhang, Zhen, additional, Xu, Rui-hua, additional, and Wang, Feng, additional

Published
2022
Full Text
View/download PDF

28. Tu1417: POST-DIAGNOSTIC MULTIVITAMIN SUPPLEMENT USE AND COLORECTAL CANCER SURVIVAL

Author

He, Ming-ming, primary, Wang, Kai, additional, Lo, Chun-Han, additional, Zhang, Yiwen, additional, Polychronidis, Georgios, additional, Knudsen, Markus, additional, Zhong, Rong, additional, Ma, Yuan, additional, Wu, Kana, additional, Chan, Andrew, additional, Giovannucci, Edward, additional, Ogino, Shuji, additional, Ng, Kimmie, additional, Meyerhardt, Jeffrey, additional, and Song, Mingyang, additional

Published
2022
Full Text
View/download PDF

29. Study on mechanical properties of granite minerals based on nanoindentation test technology

Author

Lei Man, Dang Fa-Ning, Xue Hai-Bin, Yu Zhang, and He Ming-Ming

Subjects
mechanical property, nanoindentation test, Renewable Energy, Sustainability and the Environment, TJ1-1570, Mechanical engineering and machinery, granite, fracture toughness
Abstract

In this paper, the nanoscale mechanical properties of quartz, feldspar, and mica in granite are studied by the nanoindentation technique. Firstly, the surface morphol?ogy of each mineral composition in granite is obtained by a SEM. Secondly, the elastic modulus and hardness of three minerals in granite are calculated through the load-displacement curve obtained by the nanoindentation test. Based on the energy analysis method, the nanometer fracture toughness of three minerals in granite is obtained. Finally, the correlation between the elastic modulus, the hard?ness, and the fracture toughness are obtained by experimental data.

Published
2021

30. Biomass Panel Industry Resource Utilization and Development Prospects in China.

Author

HE Ming-ming, WANG Ya-hui, LIU Zhen, WANG Jin-long, and LI Chang-gui

Subjects
BIOMASS, RAW materials, WOOD, INTERNATIONAL trade
Abstract

At present, the world wood-based panel demand is increasing year by year, the international trade environment is becoming increasingly complex, the supply of wood raw materials, seasonal raw materials, regional raw materials is tight, and biomass wood-based panel industry is facing a severe test. The main types and utilization of biomass resources based on the biomass panel industry development situation in our country was introduced. Meanwhile, the current problems and challenges were analyzed, and the prospects for development and trends were also judged, which was of great significance for the development of biomass panel industry during this new period. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Immune-Mediated Diseases Associated With Cancer Risks

Author

He, Ming-ming, primary, Lo, Chun-Han, additional, Wang, Kai, additional, Polychronidis, Georgios, additional, Wang, Liang, additional, Zhong, Rong, additional, Knudsen, Markus D., additional, Fang, Zhe, additional, and Song, Mingyang, additional

Published
2022
Full Text
View/download PDF

32. Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.

Author

Wei, Xiao-Li, Zhang, Yang, Zhao, Hong-Yun, Fang, Wen-Feng, Luo, Hui-Yan, Qiu, Miao-Zhen, He, Ming-Ming, Zou, Ben-Yan, Xie, Jie, Jin, Chun-Lei, Zhou, Xian-Feng, Wang, Feng, Wang, Feng-Hua, Li, Yu-Hong, Wang, Zhi-Qiang, and Xu, Rui-Hua

Subjects
COMBINATION drug therapy, CLINICAL trials, DRUG dosage, MONOCLONAL antibodies, ANTINEOPLASTIC agents, COLORECTAL cancer, DESCRIPTIVE statistics, RESEARCH funding, TUMORS, DRUG toxicity
Abstract

Background SHR7390 is a novel, selective MEK1/2 inhibitor. Here, we report results from two phase I trials conducted to evaluate the tolerability, safety and antitumor activity of SHR7390 monotherapy for advanced solid tumors and SHR7390 plus camrelizumab for treatment-refractory advanced or metastatic colorectal cancer (CRC). Patients and Methods Patients received SHR7390 alone or combined with fixed-dose camrelizumab (200 mg every 2 weeks) in an accelerated titration scheme to determine the maximum tolerated dose (MTD). A recommended dose for expansion was determined based on the safety and tolerability of the dose-escalation stage. The primary endpoints were dose limiting toxicity (DLT) and MTD. Results In the SHR7390 monotherapy trial, 16 patients were enrolled. DLTs were reported in the 1.0 mg cohort, and the MTD was 0.75 mg. Grade ≥3 treatment-related adverse events (TRAEs) were recorded in 4 patients (25.0%). No patients achieved objective response. In the SHR7390 combination trial, 22 patients with CRC were enrolled. One DLT was reported in the 0.5 mg cohort and the MTD was not reached. Grade ≥3 TRAEs were observed in 8 patients (36.4%), with the most common being rash (n=4). One grade 5 TRAE (increased intracranial pressure) occurred. Five patients (22.7%) achieved partial response, including one of 3 patients with MSS/MSI-L and BRAF mutant tumors, one of 15 patients with MSS/MSI-L and BRAF wild type tumors, and all 3 patients with MSI-H tumors. Conclusions SHR7390 0.5 mg plus camrelizumab showed a manageable safety profile. Preliminary clinical activity was reported regardless of MSI and BRAF status. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Reply to “The influence of multivitamin intake on survival patterns in patients with colorectal cancer”.

Author

He, Ming‐ming, Wang, Kai, and Song, Mingyang

Subjects
*MEDICAL personnel, *COLON cancer, *PHYSICAL activity, *COLORECTAL cancer, *NEOADJUVANT chemotherapy
Abstract

This document is a reply to a study titled "The influence of multivitamin intake on survival patterns in patients with colorectal cancer." The authors of the reply address the limitations of their study, including the lack of detailed treatment data and the absence of information on fatigue levels. They also mention that their findings need to be validated by further studies, preferably clinical trials. The authors disclose their conflicts of interest, and provide their contact information for correspondence. [Extracted from the article]

Published
2024
Full Text
View/download PDF

34. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment

Author

Wang, Feng, primary, Huang, You-Sheng, additional, Wu, Hao-Xiang, additional, Wang, Zi-Xian, additional, Jin, Ying, additional, Yao, Yi-Chen, additional, Chen, Yan-Xing, additional, Zhao, Qi, additional, Chen, Shifu, additional, He, Ming-Ming, additional, Luo, Hui-Yan, additional, Qiu, Miao-Zhen, additional, Wang, De-shen, additional, Wang, Feng-Hua, additional, Xu, Mingyan, additional, Li, Yu-Hong, additional, and Xu, Rui-Hua, additional

Published
2021
Full Text
View/download PDF

36. Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.

Author

Wang, Fenghua, primary, Ren, Chao, additional, Xu, Jianying, additional, Wang, Zhiqiang, additional, He, Ming-ming, additional, Qiu, Miaozhen, additional, Jin, Ying, additional, Luo, Huiyan, additional, Wang, Feng, additional, Li, Yuhong, additional, Tan, Qiong, additional, Zhang, Rong, additional, and Xu, Ruihua, additional

Published
2021
Full Text
View/download PDF

37. A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer.

Author

Wei, Xiao-li, primary, Zhang, Yang, additional, Zhao, Hongyun, additional, Wang, Zhiqiang, additional, Li, Yu-Hong, additional, Wang, Feng, additional, Wang, Fenghua, additional, Fang, Wenfeng, additional, He, Ming-ming, additional, Luo, Huiyan, additional, Qiu, Miaozhen, additional, Zou, Ben-Yan, additional, Xie, Jie, additional, Jin, Chunlei, additional, and Xu, Rui-hua, additional

Published
2021
Full Text
View/download PDF

39. Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial

Author

Ren, Chao, Mai, Zong-Jiong, Jin, Ying, He, Ming-Ming, Wang, Zhi-Qiang, Huiyan Luo, Zhang, Dong-Sheng, Wu, Chen-Yi, Wang, Feng, and Xu, Rui-Hua

Subjects
Original Article, digestive system diseases
Abstract

In the REGONIVO study, regorafenib combined with nivolumab was effective in the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), which indicated anti-angiogenic drugs may enhance the efficacy of immune checkpoint inhibitors. Therefore, we designed a single-arm, single-center, open-label, phase II trial to determine the toxicity and efficacy of SHR-1210 (an anti-PD-1 antibody) plus apatinib in MSS mCRC. The sample size was estimated using a Simon Optimum two-stage design. 10 patients were included at the first stage and if one effective patient observed, an additional 19 patients would be added. Patients with MSS mCRC who refractory to second-line treatment or intolerant to standard treatment were given SHR-1210 200 mg every 2 weeks and apatinib 250-375 mg once daily until unacceptable toxicity or disease progression occurred. In our study, the objective response rate was 0% and the disease control rate was 22.2%. The median progression-free survival was 1.83 months (95% confidence interval (CI) 1.80-1.86 months), and the median overall survival was 7.80 months (95% CI 0-17.07). Treatment-related adverse events (AEs) occurred in all patients (100%). The most common treatment-related AEs were hypertension and proteinuria (70% each). Grade 3 AEs were observed in nine patients (9/10, 90%), and the commonest was hypertension (30%). In conclusion, SHR-1210 combined with apatinib has failed to improve the efficacy of treatment of MSS mCRC, and the intolerable toxicity may be the leading cause.

Published
2020

40. Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank

Author

He, Ming‐ming, primary, Fang, Zhe, additional, Hang, Dong, additional, Wang, Feng, additional, Polychronidis, Georgios, additional, Wang, Liang, additional, Lo, Chun‐Han, additional, Wang, Kai, additional, Zhong, Rong, additional, Knudsen, Markus D., additional, Smith, Scott G., additional, Xu, Rui‐Hua, additional, and Song, Mingyang, additional

Published
2020
Full Text
View/download PDF

41. A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.

Author

Wang, Feng, primary, Xiao, Jian, additional, Zhang, Yan-Qiao, additional, Yuan, Xianglin, additional, Fang, Weijia, additional, Wang, Wei, additional, HU, Xiaohua, additional, Zhuang, Zhixiang, additional, Zhou, Fuxiang, additional, Ying, Jieer, additional, Yuan, Ying, additional, Guo, Zeng-qing, additional, Wu, XiangYuan, additional, Zou, Qing-Feng, additional, He, Ming-ming, additional, Guo, Ying, additional, Chen, Shuang-Zhen, additional, and Xu, Rui-hua, additional

Published
2020
Full Text
View/download PDF

42. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming

Author

Liu, Jia, primary, Liu, Ze-Xian, additional, Wu, Qi-Nian, additional, Lu, Yun-Xin, additional, Wong, Chau-Wei, additional, Miao, Lei, additional, Wang, Yun, additional, Wang, Zixian, additional, Jin, Ying, additional, He, Ming-Ming, additional, Ren, Chao, additional, Wang, De-Shen, additional, Chen, Dong-Liang, additional, Pu, Heng-Ying, additional, Feng, Lin, additional, Li, Bo, additional, Xie, Dan, additional, Zeng, Mu-Sheng, additional, Huang, Peng, additional, Lin, Aifu, additional, Lin, Dongxin, additional, Xu, Rui-Hua, additional, and Ju, Huai-Qiang, additional

Published
2020
Full Text
View/download PDF

43. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers

Author

Wang, Yun, primary, Lu, Jia-Huan, additional, Wang, Feng, additional, Wang, Ying-Nan, additional, He, Ming-Ming, additional, Wu, Qi-Nian, additional, Lu, Yun-Xin, additional, Yu, Hong-En, additional, Chen, Zhan-Hong, additional, Zhao, Qi, additional, Liu, Jia, additional, Chen, Yan-Xing, additional, Wang, De-Shen, additional, Sheng, Hui, additional, Liu, Ze-Xian, additional, Zeng, Zhao-Lei, additional, Xu, Rui-Hua, additional, and Ju, Huai-Qiang, additional

Published
2020
Full Text
View/download PDF

46. A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients

Author

Yang,Lu-Ping, Wang,Zi-Xian, He,Ming-Ming, Wu,Hao-Xiang, Yuan,Shu-Qiang, Wang,Wei, Jin,Ying, Ren,Chao, Wang,Zhi-Qiang, Wang,Feng-Hua, Li,Yu-Hong, Wang,Feng, and Xu,Rui-Hua

Subjects
Cancer Management and Research
Abstract

Lu-Ping Yang,1 Zi-Xian Wang,1 Ming-Ming He,1 Hao-Xiang Wu,1 Shu-Qiang Yuan,2 Wei Wang,2 Ying Jin,1 Chao Ren,1 Zhi-Qiang Wang,1 Feng-Hua Wang,1 Yu-Hong Li,1 Feng Wang,1 Rui-Hua Xu11Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People’s Republic of China; 2Department of Gastric and Pancreatic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People’s Republic of ChinaBackground: The benefit of palliative gastrectomy for patients with metastatic gastric cancer (mGC) is controversial, and suitable candidates for surgery and treatment strategies remain unclear. The present study aimed to investigate the efficacy of palliative gastrectomy plus chemotherapy among patients with mGC and to identify the potential patients for such treatment using real-world data.Methods: A dataset of 236 patients with mGC diagnosed at the Sun Yat-Sen University Cancer Center from January 1, 2006 to December 31, 2012 were analyzed retrospectively. The cohort comprised 80 patients who had palliative gastrectomy plus chemotherapy (SC) and 156 patients who had chemotherapy only (CO). Propensity score matching (PSM) was employed to minimize the influence of confounders.Results: The median overall survival of the SC group was significantly better than that of the CO group (Before PSM: 17.0months vs 12.0months, P=0.038; after PSM: 17.0months vs 13.0months, P=0.017). In the multivariate analysis, SC (Before PSM: hazard ratio (HR)=0.68, P=0.023; after PSM: HR=0.64, P=0.021) was favored for better survival after adjustment for sex, age, year of diagnosis, primary tumor location, and tumor grade. Total gastrectomy (P=0.026) was associated with worse survival for the SC group. The significant survival advantage of SC over CO was retained in patients with single organ metastasis (P=0.016), peritoneal seedings (P=0.039), and those receiving taxane-based chemotherapy (P=0.011).Conclusion: SC could improve the overall survival of patients with mGC as compared with CO. The chemotherapy regimen and type of resection were proven to influence efficacy. Patients who received taxane-based regimens might be suitable for palliative gastrectomy.Keywords: first-line chemotherapy, metastatic gastric cancer, palliative gastrectomy, propensity score matching, survival

Published
2019

48. Additional file 2: of Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer

Author

Wang, Feng, He, Ming-Ming, Zi-Xian Wang, Li, Su, Jin, Ying, Ren, Chao, Si-Mei Shi, Bing-Tian Bi, Shuang-Zhen Chen, Zhi-Da Lv, Hu, Jia-Jia, Wang, Zhi-Qiang, Wang, Feng-Hua, De-Shen Wang, Li, Yu-Hong, and Xu, Rui-Hua

Abstract

Figure S2. Mean plasma concentration–time curve of ascorbic acid after fixed-rate infusions at 0.6, 0.8, 1.0 g/min to cancer patients. After i.v. administration, the plasma concentrations of ascorbic acid rose gradually and peaked at 3 h. Cmax, and AUC values of ascorbic acid display dose-dependent increases. Ascorbic acid concentrations in the high-dose groups remained at 10–20 mmol/L for more than 4 h and showed no accumulation in the body during the administrations. (PDF 20 kb)

Published
2019
Full Text
View/download PDF

49. Additional file 3: of Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer

Author

Wang, Feng, He, Ming-Ming, Zi-Xian Wang, Li, Su, Jin, Ying, Ren, Chao, Si-Mei Shi, Bing-Tian Bi, Shuang-Zhen Chen, Zhi-Da Lv, Hu, Jia-Jia, Wang, Zhi-Qiang, Wang, Feng-Hua, De-Shen Wang, Li, Yu-Hong, and Xu, Rui-Hua

Abstract

Table S1. Pharmacokinetic values. The volumes of distribution and clearance were similar to those parameters in the fixed infusion time group. When the recommended subsequent dose was administered, the plasma concentrations of AA were maintained at 10â 20â mmol/L for more than 4â h. (DOCX 17 kb)

Published
2019
Full Text
View/download PDF

50. Additional file 1: of Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer

Author

Wang, Feng, He, Ming-Ming, Zi-Xian Wang, Li, Su, Jin, Ying, Ren, Chao, Si-Mei Shi, Bing-Tian Bi, Shuang-Zhen Chen, Zhi-Da Lv, Hu, Jia-Jia, Wang, Zhi-Qiang, Wang, Feng-Hua, De-Shen Wang, Li, Yu-Hong, and Xu, Rui-Hua

Abstract

Figure S1. Evaluation of the ascorbic acid dose proportionality in part 1 of the study. The mean AA Cmax and AUC are presented vs increasing doses of AA (measured after the first administered dose of AA) on day 1 and day 3. AUC 0â 9: area under the plasma concentration-time curve from time zero to hour 9; Cmax: maximum plasma concentration. (PDF 21 kb)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results